Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Quintiles Transnational nets $496mm through IPO

Executive Summary

CRO Quintiles Transnational Holdings Inc. has netted $496mm through its initial public offering of 13mm common shares at $40. Existing shareholders also sold 10.6mm shares and covered an overallotment of 3.6mm shares. When the company filed back in February, it had hoped to bring in about $600mm, of which half was to be used to repay a term loan.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies